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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Glanzmann’s thrombasthenia (GT) is a congenital qualitative platelet disorders 
due to the deﬁ  ciency or defect of platelet membrane GPIIb/IIIa (integrin αIIbβ3). The standard 
treatment for bleeding is platelet transfusion but repeated transfusion may result in the develop-
ment of anti-platelet antibodies (to HLA and/or GPIIbIIIa) rendering future platelet transfusion 
ineffective. Alternative effective agent(s) are needed. There are increasing reports document-
ing efﬁ  cacy of high dose rFVIIa in GT patients with adverse events uncommon. The efﬁ  cacy 
is supported by evidence that high concentration FVIIa binds to activated platelet surface and 
improves thrombin generation to enhance deposition (adhesion) and aggregation of platelets 
lacking GPIIb/IIIa. While there are increasing clinical experiences, evidence-based clinical 
data are not available. There is a need for more clinical studies, particularly clinical trials, to 
further assess the efﬁ  cacy, safety (particularly thrombotic events) and optimal regimen of rFVIIa 
in GT patients, either singly or in combination with other hemostatic agents such as platelet 
transfusion. In the absence of this data, for treatment of severe bleeding in GT patients with 
platelet antibodies and platelet refractoriness, rFVIIa at dose 90 µg/kg every 2 h for 3 or more 
doses could be considered. This more “optimal regimen” derived from a recent International 
Survey needs conﬁ  rmation with larger studies. What the optimal regimen for surgical coverage 
is remains unresolved.
Keywords: Glanzmann’s thrombasthenia, recombinant human activated factor VII (rFVIIa), 
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Introduction
Glanzmann’s thrombasthenia
Glanzmann’s thrombasthenia (GT) is a congenital bleeding disorder of platelet 
dysfunction due to the deﬁ  ciency or dysfunction of platelet membrane glycoprotein 
(GP) IIb/IIIa complex (integrin αIIbβ3). (George et al 1990; Nurden 1999) GT is a rare 
autosomal recessive disorder with an incidence of about 1:1 million, although in areas 
where marriage between close family relatives are prevalent, the incidence is much 
higher. The genetic defect can be on the GPIIb or GPIIIa gene and homozygosity of 
the same mutation are more likely a result of consanguineous marriage, while many 
other patients may be compound heterozygous for different mutations from each par-
ent. Bleeding symptoms are conﬁ  ned to GT patients with homozygous or compound 
heterozygous for GPIIb/IIIa mutations. Heterozygotes are asymptomatic, so that family 
history of bleeding may be absent.
GPIIb/IIIa complex is involved with platelet aggregation mediated primarily by the 
binding of ﬁ  brinogen to this glycoprotein complex on activated platelets (Peerschke Vascular Health and Risk Management 2006:2(4) 465–475
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et al 1980). Thus absence of platelet aggregation in response 
to physiologic agonists such as adenosine-5'-phosphate 
(ADP), epinephrine, collagen and thrombin is the hallmark 
laboratory abnormality. The diagnosis can be conﬁ  rmed by 
ﬂ  ow cytometry using monoclonal antibodies to GPIIb, GPIIIa 
or intact GPIIa/IIIa complex. For convenience, GT can be 
classiﬁ  ed according to the platelet membrane GPIIb/IIIa 
levels, being <5% for type I disease, 5%–15% for type II 
disease and higher for variant disease which is a result of 
dysfunction rather than a deﬁ  ciency of the GPIIb/IIIa com-
plex. Asymptomatic heterozygotes usually have about 50% 
platelet membrane GPIIb/IIIa.
Bleeding symptoms has been reviewed by George et al 
in 1990 (George et al 1990) on 113 patients. The most com-
mon symptoms are menorrhagia (98%), easy bruising and 
purpura (86%), epistaxis (73%) and gingival bleeding (55%). 
Less common are gastrointestinal bleeding (12%), hematuria 
(6%) while hemarthrosis (3%), intracranial bleeding (2%) 
and deep visceral bleeding (1%) are rare. Although bleed-
ing manifestations are variable, and occasional patients may 
have very mild symptoms, overall, GT is a severe bleeding 
disorder, as majority of patients would have a history of 
red cell and/or platelet transfusion. Epistaxis is common 
particularly in children and can be severe requiring transfu-
sion. Menorrhagia could be a critical bleeding problem with 
a particularly high risk of severe and prolonged bleeding 
requiring transfusion at menarche.
Management options for the treatment of GT bleeding 
include conservative measures for mild bleeding. These 
include the use of local pressure including nasal packing with 
gelatin sponge for epistaxis, local hemostatics such as ﬁ  brin 
glue and topical thrombin, as well as the use of antiﬁ  brinolyt-
ics. The standard treatment for serious bleeding is platelet 
transfusion. There are also anecdotal reports of success with 
DDAVP, but DDAVP is often not effective.
The use of platelets however can be complicated by the 
development of allo-antibodies to GPIIb/IIIa and/or antigens of 
the HLA system. For this reason, single-donor HLA-matched 
platelet transfusion is preferred over random donor platelets so 
as to at least delay or prevent HLA allo-immunization, even 
though antibodies to GPIIb/IIIa may still develop. Patients 
with platelet antibodies can become refractory to future platelet 
transfusion treatments. Furthermore, anti-GPIIb/IIIa antibodies 
may cross the placenta in pregnant women resulting in neonatal 
thrombocytopenia and/or bleeding in the fetuses or newborns, 
including intracranial bleeding. Platelet concentrates, as a 
blood product that must be stored at room temperature can 
also be associated with blood-borne infections. The residual 
risk of blood-borne virus infection is now minimal (Dodd 
et al 2002). Bacterial contamination of platelet concentrates, 
on the other hand, could be as high as 1 in 2000 to 3000 units 
and one out of six of the contaminated units transfused may 
result in severe septic reactions. (Jacobs et al 2001) An alter-
native effective agent is therefore needed for management of 
GT patients particularly those who are refractory to platelet 
transfusion and in patients who live in areas where platelets 
are not readily available.
Recombinant human activated factor 
VIIa (rFVIIa)
Recombinant Human activated Factor VIIa (rFVIIa, NovoSeven/
Niastase, Novo Nordisk A/S, Bagsvaerd, Denmark) is produced 
by recombinant DNA technology in baby hamster kidney (BHK) 
cells cultured in a medium containing fetal calf serum, but no 
human proteins or derivatives (Jurlander et al 2001) so that 
human pathogen transmission is not a risk. The ﬁ  nal product has 
a speciﬁ  c activity of approximately 50,000 IU/mg. As a refer-
ence, average normal plasma contains 1 U FVII activity (plasma 
concentrations of FVII and FVIIa are respectively 10 nM and 
0.1 nM) (Morrissey and Mutch 2006). The median in vivo recov-
ery of rFVIIa after infusion at doses 17.5–70 µg/kg in the bleed-
ing and nonbleeding state was determined to be approximately 
46% and 44%, respectively (Lindley et al 1994).
rFVIIa exerts its hemostatic effect only after complexing 
with tissue-factor (TF). TF is normally not exposed to ﬂ  owing 
blood, but is found in various cells in the deeper layer of the 
blood vessel wall. (Morrissey and Mutch 2006) Clotting is 
initiated at the wound site after tissue injury and complexing 
of FVIIa with the exposed TF. Under normal physiological 
circumstances, rFVIIa is otherwise proteolytically inert in 
the circulation and infusion of rFVIIa does not appear to 
cause systemic activation of coagulation except in unusual 
circumstances. Other cells that express TF include some 
tumor cells as well as monocytes and neutrophils that have 
been stimulated by bacterial endotoxin and certain other 
inﬂ  ammatory mediators. (Morrissey and Mutch 2006) Stud-
ies in rabbit stasis model at rFVIIa doses 100–1000 µg/kg 
showed no signiﬁ  cant clot formation over 10 minutes of 
stasis. (Diness et al 1992) Signiﬁ  cant platelet and ﬁ  brinogen 
changes were not observed 3 hours after infusion. Turacek 
et al (1997) conﬁ  rmed in a similar Rabbit stasis model rFVIIa 
to have low thrombogenic potential, which was enhanced by 
the addition of soluble TF.
Pharmacokinetic studies in adult hemophilia patients with 
or without inhibitors show this agent, when given at doses 
17.5–70 µg/kg, to have a relatively short half-life (T1/2), at 2.3 Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
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rFVIIa in Glanzmann’s thrombasthenia
and 2.9 hours respectively in the bleeding and non-bleeding 
state.(Lindley et al 1994) Similar T1/2 (3.0 h) was obtained 
in patients with factor VII deﬁ  ciency (Berrettini et al 2001). 
The T1/2 in children at a dose of 90–180 µg/kg was similar 
at 2.6 hr.(Villar et al 2004) The short T1/2 makes it necessary 
to give this agent at frequent short-intervals.
rFVIIa is currently approved for the treatment of 
hemophilia A or B patients with inhibitors in many countries 
including New Zealand, Australia, Japan and those in North 
America, and Europe. It is also approved in the European 
Union (EU) for treatment of patients with acquired hemo-
philia, Factor VII deﬁ  ciency and GT with history of platelet 
antibodies (to GPIIb/IIIa and/or HLA) and past or present 
history of platelet refractoriness and in the US for bleeding 
in Factor VII deﬁ  ciency.
Mechanism of action of rFVIIa in patients 
with Glanzmann’s thrombasthenia
Physiologically, FVIIa exerts its hemostatic effect after com-
plexing with TF. In normal persons, FVIIa-TF complex on 
TF-bearing cells at the site of vascular injury activates FX 
and FIX resulting in initial thrombin generation that activates 
a number of clotting factors (eg, FV, FVIII, FXI) as well as 
platelets. Activated platelets are recruited to the wound site 
where they aggregate, mediated in part by binding of soluble 
ﬁ  brinogen to platelet surface GPIIb/IIIa (Phillips et al 1988), 
for primary hemostatic plug formation. Activated platelets 
at the wound site support further coagulation activation 
resulting in sufﬁ  cient thrombin generation (thrombin burst) 
for ﬁ  brin formation and hemostasis (Hoffman et al 1998). In 
GT, this TF mechanism is important in generating the initial 
thrombin on TF-bearing cells at the site of tissue injury for 
initiating platelet activation. However, this small amount of 
thrombin generation is not sufﬁ  cient in GT to result in platelet 
aggregation to support sufﬁ  cient thrombin burst at the wound 
site, because of the lack of GPIIbIIIa receptors for ﬁ  brinogen 
binding. GT platelets have thus been shown to have impaired 
thrombin generation capacity (Reverter et al 1996; Dargaud 
et al 2006). Experimental evidence suggests that high dose 
rFVIIa effect hemostasis in GT via a TF independent mecha-
nism. High dose rFVIIa can bind to activated platelet surface 
with a low afﬁ  nity (Kd ∼ 100 nM).(Monroe et al 1997) At 
high concentration, the bound rFVIIa could directly activate 
FX to FXa resulting in bursts of thrombin generation sufﬁ  -
cient to convert ﬁ  brinogen to ﬁ  brin. In experimental models, 
this thrombin burst mediated by rFVIIa bound to activated GT 
platelet surface was shown to allow for further platelet activa-
tion, and enhancement of adhesion and aggregation of the 
Glanzmann’s thrombasthenia platelets (Lisman et al 2003, 
2004) (Figure 1). The enhanced adhesion of Glanzmann’s 
thrombasthenia platelets appear to require the participation 
of von Willebrand factor-GPIb interaction, mediated also by 
enhanced thrombin generation.(Lisman et al 2003) Despite 
the lack of surface GPIIb/IIIa, and therefore unable to bind 
soluble ﬁ  brinogen, GT platelets have been shown to agglu-
tinate in the presence of ﬁ  brin, particularly polymeric ﬁ  brin 
(Niewiarowski et al 1981; McGregor et al 1989; Osdoit and 
Rosa 2001). Lisman and his colleague (Lisman et al 2004) 
showed that GT platelets aggregated in parallel with ﬁ  brin 
conversion related to thrombin generation mediated by 
rFVIIa bound to activated GT platelet surface. This ﬁ  brin 
mediated GT platelet aggregation was partially dependent 
on binding of thrombin to GPIb (Lisman et al 2004) shown 
in normal platelets to mediate binding of ﬁ  brin to an as yet 
unidentiﬁ  ed receptor. Fibrin appeared an active participant in 
mediating platelet aggregation partly in a receptor-mediated 
manner, as opposed to being passively trapped during platelet 
aggregation, since aggregation was less efﬁ  cient if viable 
platelets were replaced by ﬁ  xed platelets.
rFVIIa in the treatment 
and prevention of bleeding 
in Glanzmann’s thrombasthenia 
patients
Tengborn and Petruson (1996) were the ﬁ  rst to use rFVIIa 
to successfully treat a hereditary platelet disorder in a 
child with GT and severe epistaxis. Since then there have 
been a large number of reports on efﬁ  cacy of rFVIIa in GT 
(Poon et al 1999; Chuansumrit et al 1999, 2003; Robinson 
et al 2000; d’Oiron et al 2000; Monte and Lyons 2002; 
van Buuren and Wielenga 2002; Almeida et al 2003; 
Caglar et al 2003; Bell and Savidge 2003; Poon et al 
2004; Kaleelrahman et al 2004; Kale et al 2004; Uzunlar 
et al 2004; Coppola et al 2004; Yilmaz et al 2005; Dargaud 
et al 2006; Inagaki et al 2006; Lombardo and Sottilotta 
2006) as well as other platelet function disorders including 
Bernard Soulier Syndrome (Peters and Heijboer 1998; 
Almeida et al 2003; Kaleelrahman et al 2004; Ozelo et al 
2005); platelet storage pool defect including Hermansky-
Pudlak syndrome (Pozo Pozo et al 2002; Almeida et al 2003; 
Langendonck and Appel 2005), and platelet-type (pseudo) 
von Willebrand disease (Fressinaud et al 1998).
In 1999, we reported a pilot prospective open-label 
Canadian study on 4 children treated for 24 bleeding 
episodes (3 GI, 13 nose, 7 oropharynx and 1 traumatic facial Vascular Health and Risk Management 2006:2(4) 465–475
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hematoma) and one herniorrhaphy treated with rFVIIa at 
89–116 µg/kg every two hours. (Poon et al 1999). The study 
was initiated because one of the participating children had 
required frequent admission to intensive care unit for severe 
epistaxes with hemoglobin dropping to as low as 40 g/L 
and had become refractory to platelet transfusion because 
of the development of antibodies against GPIIb/IIIa. In this 
study, the severity of some of the bleedings was indicated 
by the need for red cell transfusion in all 3 GI bleeds and 
in 4 epistaxes. Bleeding stopped promptly or within 6 hr of 
starting rFVIIa in 16 bleeding episodes (67%) and in less 
than 24 h in another 7 episodes. The remaining one GI bleed 
failed to respond to 24 every-two-hour doses and required 
rescue with platelet transfusion. Two bleeds, one GI and 
one frenulum/lip cut, each initially stopped after 3 rFVIIa 
doses at 4 and 5 hours respectively, recurred at 36 and 63 
hours later. In both cases, bleeding stopped after additional 
doses without rebleeding. The herniorrhaphy was managed 
with one dose preoperatively and one dose 2 hours later 
without perioperative or postoperative bleeding and the 
patient was discharged 36 hours postoperatively with minor 
ecchymoses at the wound site. Antiﬁ  brinolytic drugs were 
given concurrently with rFVIIa in all but two minor bleeding 
episodes, one with oropharyngeal bleed and one with facial 
hematoma. No thrombotic adverse event was noted.
A British study of ﬁ  ve GT patients (Almeida et al 2003) 
showed more variable results with good/excellent results in 
only 12 of the 25 bleeding episodes, but all three surgical 
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Figure 1 Schematic tissue factor-independent, platelet-dependent model of primary hemostatic plug formation in Glanzmann’s thrombasthenia (GT) platelets deﬁ  cient in 
membrane glycoprotein (GP) IIb-IIIa (integrin αIIbβ3). FVIIa-tissue factor (TF) complex on TF-bearing cells at the site of vascular injury activates FX to FXa, which in turn 
complexes with FVa on the TF-bearing cells to initiate generation of a small amount of thrombin (FIIa) from prothrombin (FII). This initially generated thrombin is not 
sufﬁ  cient to allow ﬁ  brin formation, but is sufﬁ  cient to activate the GT platelets, causing degranulation and release of FV. FVIIa binds to activated platelets weakly. At high 
concentration (eg, high dose rFVIIa therapy), the bound FVIIa can directly activate FX to FXa to mediate generation of high concentration of thrombin (thrombin burst). 
The augmented thrombin generation results in increased number of activated platelets deposited (adhesion) to the wound site, and increased available platelet procoagulant 
surface to facilitate more thrombin generation and more platelet activation. The augmented thrombin generated also converts ﬁ  brinogen to ﬁ  brin.   Activated GT platelets 
cannot utilize ﬁ  brinogen for aggregation reaction as they lack the ﬁ  brinogen receptor integrin αIIbβ3.  However, binding of ﬁ  brin/polymeric ﬁ  brin to an as yet unidentiﬁ  ed 
platelet surface receptor can mediate aggregation of the GT platelets at the wound site (even though less potent than ﬁ  brinogen mediated aggregation of normal platelets) 
resulting in primary hemostatic plug formation.   Adapted from Poon (2006).Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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procedures were successfully covered. Further analysis of the 
data showed an important observation. The poor results could 
be related to delayed treatment, as good/excellent responses 
were observed in 10 of their 14 episodes (71%) treated within 
12 hours of bleeding onset, but in only two of 11 (18%) 
treated after 12 h. This study underlines the importance of 
early treatment as has also been observed when rFVIIa were 
used to treat hemophilia patients with inhibitors for muscle, 
joint and mucocutaneous bleeds. (Lusher 1998; Santagostino 
et al 1999; Lusher 2000).
International survey on the use of rFVIIa 
in the treatment and prevention 
of bleeding in GT
Randomized trials would have been helpful to evaluate the 
effectiveness and risk-beneﬁ  t of rFVIIa in GT. However, 
such studies are hindered by the rarity of GT. Moreover, 
many bleeds in GT can be treated with local measures and/or 
antiﬁ  brinolytic drugs and the number of bleeds requirimg 
the use of systemic hemostatic treatment is not high. We 
(Coordinators: M-C Poon and R d’Oiron) began an interna-
tional survey in 1999 to better assess the efﬁ  cacy and safety 
of rFVIIa in GT patients. There was wide participation from 
49 centers in 17 countries, providing data that include some 
previously published cases.(Tengborn and Petruson 1996; 
Musso et al 1999; Poon et al 1999; d’Oiron et al 2000; 
Robinson et al 2000; Almeida et al 2003; Devecioglu et al 
2003) The survey data analyzed for reporting in 2004 (Poon 
et al 2004) include 59 patients treated for 108 bleeding 
episodes and 34 invasive procedures. There are limitations 
on this kind of survey that need to take into account in the 
interpretation of the data. These include the heterogeneity 
of treatment regimens used since management was at the 
discretion of the investigators, the different guidelines for the 
minimum rFVIIa doses to be used before declaring failure 
and switching to other available treatment product(s), and 
the lack of data on the time between bleeding onset and treat-
ment initiation. Also, although investigators were asked to 
report all positive and negative experiences, the possibility 
for under-reporting of negative experience still could not be 
excluded. Nonetheless, useful information and observations 
were obtained.
The 59 patients treated include 24 males and 35 females, 
aged 1–72 years (median 22) including 27 children (age 
15 years or younger). The majority of patients had type I dis-
ease (39 of 49 known) and 35 patients had platelet antibodies 
(to GPIIb/IIIa and/or HLA) and/or platelet refractoriness.
Data on bleeding episodes
Of the 108 bleeding episodes, 76 were severe and 32 were 
moderate. Bleeding was considered severe if it was intracra-
nial, resulted from severe trauma, compressed a vital organ, 
or led to a fall in hemoglobin level of 20 g/L or more within 4 
days. Bleeds that require systemic hemostatic treatment other 
than antiﬁ  brinolytic drugs, but did not ﬁ  t at least one of these 
criteria were considered moderate. These 108 bleeds include 
17 from the gastrointestinal tract (GI, 16 severe, 1 mild), 45 
nose (32 severe, 13 moderate), 29 oropharynx (19 severe, 10 
moderate), and 17 miscellaneous sites (9 severe, 8 moderate). 
As indicated in Table 1, 5 successfully treated episodes (2 nose 
bleeds and 3 bleeding in miscellaneous sites) were not evalu-
able due to confounding by concurrent platelet transfusion. 
The response (cessation of bleeding) rate among the evaluable 
patients was 53%, 74%, 79%, and 93% respectively for bleed-
ing from the GI tract, nose, oropharynx and miscellaneous sites 
(Table 1). The overall response rate for intention to treat and 
response rate for evaluable episodes were respectively 71% 
and 75%, However, 8 of 77 episodes that stopped bleeding 
had a recurrence, so that the overall success rate when the 
recurrences were excluded was 64% for intention-to-tread and 
67% for evaluable episodes, and was much lower than that 
observed in the pilot Canadian study (Poon et al 1999). Here, 
several clinically relevant observations were made:
Some rFVIIa treatment regimens are better than others
Of note is that 10 of the 26 failures were declared after a 
one or two bolus dose of rFVIIa (n = 5 each), so that the 
rFVIIa treatment may not have been sufﬁ  cient. Indeed, when 
evaluable bleeds were analyzed according to the treatment 
regimen, the overall success (without recurrences) rate 
in the 41 severe and moderate bleeds treated with bolus 
rFVIIa dose of at least 80 µg/kg, at interval of 2.5 h or less 
for at least 3 doses was 78% (32/41), compared with 60% 
(37/62) with other rFVIIa regimens including rFVIIa given 
by continuous infusion. For severe bleeds, the success rate 
using this arbitrary but more “optimal” regimen was 77% 
(24/31) and was signiﬁ  cantly higher than the 55% (18/33) 
(p = 0.01) for regimens using lower dose or longer dosing 
intervals or less number of doses or when continuous infu-
sion was used. It is therefore not surprising that Inagaki et al 
(Inagaki et al 2006) found that a single dose of rFVIIa, while 
effective in stopping a mild epistaxis was not effective for 
a severe prolonged epistaxis. Thus, for severe bleeds when 
rFVIIa is used, doses at about 90 µg/kg or higher, every 
2 h for a minimum of 3 doses until bleeding stops should 
therefore be considered. In the treatment of hemophilia with Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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inhibitors, Kenet et al (2003) showed that megadose rFVIIa 
at 300 µg/kg may be more effective than the standard rFVIIa 
dose of 90 µg/kg. It is therefore reasonable that a higher dose 
rFVIIa up to 300 µg/kg can be tried in patients who fail after 
several standard doses, but there is at this time no trial study 
data to support this contention. In clinical practice, how a 
patient is managed and when treatment should be switched 
will obviously depend on the ready availability of various 
treatment options and knowledge of relative efﬁ  cacy, risk 
and cost of each.
Continuous infusion is not effective in stopping bleeding
Continuous infusion appears ineffective to stop bleeding, as 6 
of 7 CI treatments of evaluable bleeding episodes failed. The 
failures include 4 GI bleeds, one nose and one post-intubation 
pharyngolarygeal bleed using doses up to 32 µg/kg/h (after 
initial bolus) for up to 22 days. One GI bleed did respond to 
40 µg/kg/h CI (after initial bolus) carried out for 60 hours 
with bleeding stopped at 24 h. The number of episode treated 
was too small for analysis of CI dose effect.
Maintenance doses are useful particularly 
for severe bleeds
The recurrence rate could apparently be decreased by the use 
of maintenance doses after bleeding stopped. Only one of the 
8 episodes (13%) that stopped but with a recurrence received 
a maintenance dose. On the contrary, in the 62 episodes that 
bleeding stopped without a recurrence (and with the timing 
of bleeding cessation and rFVIIa discontinuation known) 36 
(58%) received maintenance doses (p = 0.022). One to three 
(or more) maintenance doses at 90 µg/kg or higher (similar to 
the treatment dosage), every 2–3 hourly should therefore be 
considered for severe bleeding episodes, bleeding related to 
severe trauma and GI bleeds even though the bleeding may 
stop after one or two doses.
GI bleeding is particularly difﬁ  cult to treat
Only 9 of 17 GI bleeding episodes stopped, of which one 
recurred 36 hr later. The 8 failures may be related to the severity 
of the GI lesion as there were 3 angiodysplasia, one Mallory-
Weiss syndrome and one radiation gut injury. The treatment may 
also be inadequate in some episodes; one episode was declared 
failure after received a single dose rFVIIa, while 4 were treated 
by continuous infusion. One additional patient was given 3 doses 
then stopped despite continuing bleeding.
Use of antiﬁ  brinolytic drugs
Antiﬁ  brinolytic drugs were given concurrently with rFVIIa in 
12 of 17 GI bleeds and 70 of 91 non-GI bleeds. The success 
rate for those receiving concurrent antiﬁ  brinolytic drugs 
were similar to those not receiving antiﬁ  brinolytic drugs. 
On general principle, the use of antiﬁ  brinolytic agents in 
conjunction with rFVIIa should be considered at least for 
muscosal bleeds when there is no contraindication such as 
bleeding in the urinary tract. In the survey, one episodes 
of post-intubation pharyngolaryngeal bleed stopped only 
when antiﬁ  brinolytic drug was added after failing 9 days of 
continuous rFVIIa infusion.
Possibility of using rFVIIa as ﬁ  rst-line therapy
A high proportion (58/80 or 83%) of the successfully treated 
bleeds stopped within 6 hours (0.1–6 hours) after the ﬁ  rst 
rFVIIa injection, suggesting that rFVIIa could be used as 
ﬁ  rst-line therapy while waiting for the availability of adequate 
apheresis platelet concentrates. On the contrary, in patients 
Table 1 Outcome of rFVIIa treatment for 34 surgical procedures and 108 bleeding episodes in patients with Glanzmann’s thrombas-
thenia (data from Poon et al (2004))
Category N  Responsea Recurrencec Failured Not 
   (rate  %)b     evaluablee
Bleeding episodes (all)  108  77(71/75)  8  26  5
GI 17  9(53/53)  1  8  0
Epistaxes 45  32(71/74)  4  11  2
Oropharynx 29  23(79/79)  2  6  0
Miscellaneous sites  17  13(76/93)  1  1  3
Surgical procedures (all)  34  29(85/94)    2  3
Major 9  6(67/86)    1  2
Minor – dental extraction  9  9(100/100)    0  0
Minor – others  16  14(88/93)    1  1
aResponse = cessation of bleeding within 48 h of initiation of rFVIIa treatment.
b(intention-to-treat response rate in % / response rate of evaluable episodes in %).
cRecurrence = bleeding that stopped in ≤48 h but with recurrence of bleeding in ≤48 h following cessation of initial bleeding.
dFailure = Bleeding that stopped more than 48 h after the initiation of rFVIIa treatment and/or if another treatment (other than antiﬁ  brinolytic drugs) was needed.
eNot evaluable = platelet transfusion(s) were given concurrently with rFVIIa.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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with anti-platelet antibodies and refractory to platelet transfu-
sion, high-dose HLA-compatible platelets transfusions, with 
or without antibody removal therapy (Ito et al 1991; Martin 
et al 2002), should not be delayed in case of life-threatening 
bleeding or when rFVIIa therapy fails.
Data on invasive procedures
Of the 34 surgical procedures covered with rFVIIa, 9 were 
major, 25 were minor. Two major and one minor successful 
procedures were not evaluable due to confounding by 
concurrent platelet transfusion. Of the 7 evaluable major 
procedures covered with rFVIIa, 6 were successful, 3 
by bolus rFVIIa injection and 3 by continuous infusions 
(Tables 1 and 2). Of the 24 evaluable minor procedures 
treated, 23 were successful, 20 by bolus injection and 3 by 
continuous infusion (Tables 1 and 2). Thus the intention-to-
treat success rate for the 34 procedures was 85%, and the 
success rate for the 31 evaluable episodes was 94%. The 
following observations are made:
Dental extractions
Dental extractions are frequent minor procedures. In this 
survey, all 9 dental extractions were successfully covered 
by bolus injections using, in median (range), rFVIIa dose 
of 100 µg/kg (78–134) for 3 doses (1–19) and treatment 
duration of 6 h (0.1–152) (Table 2). The ﬁ  rst dose was 
obviously given immediately or shortly before the procedure 
with subsequent doses given mostly at 2 h interval. Although 
some episodes were covered with only the initial dose with 
no further injection because there was no bleeding, in general 
1 or more maintenance dose(s) were given following the 
procedure. Antiﬁ  brinolytic agents were given concurrently 
with rFVIIa in all the 9 dental extractions.
Continuous Infusion (CI) is effective but not necessarily 
advantageous compared to bolus injections
Unlike treatment of bleeding episodes where continuous 
infusion appears ineffective, CI was effective in preventing 
bleeding in all 6 surgical procedures. However, although 
CI was used with the intention to avoid the valley and peak 
rFVIIa concentrations that would theoretically save on factor 
concentrates, in fact, CI resulted in longer treatment duration 
(Table 2). Objective data on reasons for the longer treatment 
are lacking. It is tempting to speculate that perhaps once CI 
has been initiated and became routine, it became more likely 
to let the routine continued in the absence of bleeding, but 
again supporting data is lacking. Thus, the total rFVIIa usage 
was higher in CI than in bolus injection treatment with the 
median (range) for major procedures 1779 µg (1182–10080) 
by CI vs. 1288 µg (368–2640) by bolus; and for minor pro-
cedures 948 µg (715–2376) by CI vs 300 µg (112–2042) by 
bolus. As indicated in the Adverse Event section, the only 
adverse events in this study were in patients receiving high-
dose CI for a prolonged period following major surgery.
Use of antiﬁ  brinolytic drugs
Antiﬁ  brinolytic drugs were used concurrently with rFVIIa in 27 
of the 34 procedures. The drug was omitted in 4 minor and 3 
Table 2 Invasive procedures (N = 29) successfully treated with rFVIIa as ﬁ  rst-line therapy (3 non-evaluablea episodes and 2 failuresb 
not included) (data from Poon (2004))
Bolus injections  Median  Continuous infusion  Median
 (range)    (range)
Major surgery: all 3 episodesc   Major Surgery: all 3 episodesd 
Dosage (µg/kg per injection)  92(80–92)  Initial bolus dosage (µg/kg)  49(28–70)
Doses used (N)  14(4–33)  CI dosage (µg/kg/h)  5(5–30)
Duration of treatment (h)  47(11–141)  Duration of treatment (h)  282(225–336)
Minor surgery: all 20 epidsodese   Minor surgery: all 3 episodesf 
Dosage (µg/kg per injection)  109(74–150)  Initial bolus dosage (µg/kg)  88(72–110)
Doses used (N)  3(1–19)  CI dosage (µg/kg/h)  12(9–20)
Duration of treatment (h)  7(0.1–152)  Duration of treatment (h)  67(60–267)
Minor surgery: 9 dental extraction    
Dosage (µg/kg per injection)  100(78–134)   
Doses used (N)  3(1–19)   
Duration of treatment (h)  6(0.1–152)   
aNonevaluables: two major (pyelonephrectomy, skin grafting) and 1 minor (central catheter insertion).
bFailures: persistent oozing after endoscopic uterine myometomy; recurrent hematuria following ureteric stent removal.
cMajor by bolus injection: laparotomy, laparoscopic bilateral oophorectomy, hysterectomy.
dMajor by CI: colostomy, colostomy revision, intestinal resection.
eMinor by bolus injection: Nine dental extractions, 4 other dental procedures, 2 colonoscopy/polypectomy, one each of cystoscopy/ureteric stent insertion, hernia repair, 
tracheostomy, knee injection, otolaryngological cryosurgery.
fMinor by CI: central cathetre removal, colonoscopy/polypectomy, cystoscopy/ureteric stent insertion.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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major procedures including 3 that would have been contraindi-
cated because the surgical site involved the urinary tract and one 
procedure that was done on a patient with preexisting coronary 
disease. The data is insufﬁ  cient to analyze the contribution of 
antiﬁ  brinolytics in preventing surgical bleeding. None-the-less, 
in the absence of contraindications, antiﬁ  brinolytics should be 
considered for surgery involving mucosal sites and in dental 
extractions/procedures where there are no contra-indications. 
In this survey, as indicted earlier, antiﬁ  brinolytics were used 
in all the 9 successful dental extractions.
Is there an optimal regimen?
The number of surgical procedures treated with rFVIIa 
remains relatively small such that an optimal regimen could 
not be derived from the available data.
Unresolved issues
There are unresolved issues raised by this survey. One already 
stated is the inability to determine the optimal rFVIIa regimen 
for surgical coverage in GT patients. In addition, although 
some preliminary suggestions for the optimal rFVIIa regi-
men in bleeding episodes can be derived from the analysis, 
conﬁ  rmation from larger studies will be required. There are 
also insufﬁ  cient data to evaluate the safety of rFVIIa in GT 
patients, particularly with regard to the incidence of throm-
boembolic events.
In 2004, the European Medical Evaluation Agency (EMEA) 
approved the use of rFVIIa for European Union patients 
with GT with platelet antibodies and past and/or present 
history of platelet refractoriness. As required by the EMEA, 
an international post-marketing pharmacovigilance study 
(http://www.glanzmann-reg.org) has recently been launched 
to assess the efﬁ  cacy and safety of rFVIIa and other systemic 
hemostatic agents (including platelet transfusion) on a larger 
number of GT patients with or without platelet antibodies or 
platelet refractoriness (Poon 2006). The study is open to any 
interested investigator both within and outside Europe.
Adverse events
rFVIIa when used in patients with Glanzmann’s thrombas-
thenia appears to be safe. In the International survey (Poon 
et al 2004), a 72-year old woman with GT developed deep vein 
thrombosis and pulmonary embolism after bowel resection 
surgery covered with rFVIIa (d’Oiron et al 2000). She received 
a bolus of 90 µg/kg rFVIIa followed by high dose continuous 
infusion at 30 µg/kg/h for 16 hours. The thrombotic event 
occurred 6 days after rFVIIa was discontinued. Another 
23-year old woman with GT developed clots in the right renal 
pelvis and ureter after gynecological surgery covered with 
rFVIIa by continuous infusion (25 µg/kg/h tapered gradually 
to 12 µg/kg/h for 4 days, and antiﬁ  brinolytics (Robinson 
et al 2000). This patient likely had inadvertent trauma to the 
kidney during surgery, with bleeding and clotting in the renal 
pelvis and ureter that did not lyse. This does not represent 
an intravascular clotting complication. Among patients with 
other platelet disorders receiving rFVIIa, thrombotic events 
in one patient with Bernard-Soulier syndrome and one with 
uremic dysfunction have been reported to the US Food and 
Drug Administration (FDA) MedWatch Pharmacovigilance 
Program (Aledort 2004).
rFVIIa has been used more extensively in hemophilia 
patients with inhibitors and thrombotic complications are 
rare except in unusual circumstances (Abshire and Kenet 
2004; Aledort 2004). Abshire and Kenet (2004) reviewed 
20 thrombotic and 5 DIC events reported spontaneously to 
the manufacturers, reported in clinical trials or reported in 
the literature. The amount of rFVIIa administered between 
1996 and April 2003 to hemophilia patients (number not 
speciﬁ  ed) was more than 700,000 standard doses of rFVIIa 
(each equivalent to 90 µg/kg × 40 kg). Most of these patients 
apparently had comorbid or predisposing factor, such as 
diabetes mellitus, coronary artery disease, atherosclerosis, 
hypertension, obesity, advanced age or indwelling catheter or 
other DIC risk. rFVIIa has also been used on an investigational 
basis (off-label) for diverse bleeding situation in patients 
without hemophilia or congenital bleeding disorders, including 
GI, intracranial and postoperative bleeds; bleeding after trauma 
or after bone marrow/stem cell or organ transplantation. 
Thirty-eight thrombotic events were reported to the FDA 
MedWatch Pharmacovigilance Program or as published case 
reports between April 1999 and June 2000 (Aledort 2004; 
Sallah et al 2005). O’Connell et al (2006) reviewed adverse 
events related to rFVIIa use reported to the US FDA Adverse 
Event Reporting system from March 25, 1999 to December 
31, 2005. They found 220 reports on 246 thromboembolic 
events (23 reports in hemophilia and 197 reports in off-label 
indications) that included 129(52%) arterial events (non 
hemorrhagic intracranial cerebrovascular accident, acute 
myocardial infarction, other arterial thromboembolism), 
100(41%) venous events (including deep vein thrombosis 
and pulmonary embolism), 15(6%) devise occlusion and 
2(1%) with sites not stated. Forty-three of the 67 deaths were 
probably related to thromboembolic events. In all series, the 
contribution of patient factors as well as other hemostatic 
agents that might have been used, relative to rFVIIa use, in 
these adverse events was not clear, so that the true incidence Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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rFVIIa in Glanzmann’s thrombasthenia
of rFVII-related thrombosis remains unknown. Finally, in a 
clinical trial of 399 patients with intracranial bleeds, arterial 
thrombosis (primarily myocardial ischemia and cerebral 
infarct) was signiﬁ  cantly higher in the rFVIIa group (16 of 
303, 5%) compared to the controls (0 of 96, 0%) while venous 
thrombosis were the same.(Mayer et al 2005) The incidence 
of arterial thrombosis at rFVIIa dose of 40, 80 and 160 µg/kg 
in this study were respectively 6%, 2% and 8%.
Irrespective, it is expected that correction of the hemostatic 
defect may predispose the patient (with bleeding disorders) to 
thrombosis if predisposing factors are present. Thus, caution 
should be exercised when using rFVIIa in patients with under-
lying conditions that may predispose them to arterial or venous 
thrombosis, or DIC and in patients with advanced age. 
Conclusion
High dose rFVIIa has been shown to have documented 
efﬁ  cacy for the treatment and prevention of bleeding in 
patients with Glanzmann’s thrombasthenia. Experimental 
evidences are emerging suggesting that high dose rFVIIa 
improves thrombin generation, though not necessarily 
to normal levels, resulting in enhanced adhesion and 
aggregation of GT platelets that do not respond to 
physiologic aggregating agents because of the lack of 
the ﬁ  brinogen receptor GPIIbIIIa. At this time, high dose 
rFVIIa is indicated for GT patients who have development 
anti-platelet antibodies (to HLA and/or GPIIbIIIa) 
and history of past or present refractoriness to platelet 
transfusion. High dose rFVIIa could also be considered 
for situations where avoidance of anti-platelet antibodies 
development is important or desirable. One such example 
is female patients approaching and during reproductive age 
when development of anti-GPIIbIIIa antibodies capable of 
passing through the placenta during pregnancy may result 
in fetal/neonatal thrombocytopenia and serious bleeding 
(including intracranial bleeding). As indicated earlier, the 
International Survey data on Glanzmann’s thrombasthenia 
allow a preliminary suggestion of a more optimal regimen 
for treatment of bleeding episodes, but the appropriate 
regimen for surgical prophylaxis remains unknown. The 
experience on the use of rFVIIa in GT patients is also too 
limited to allow proper assessment of safety of rFVIIa. There 
is, therefore, a major need for clinical studies, particularly 
clinical trials, to assess efficacy, safety (particularly 
thrombotic events) and to provide evidence-based optimal 
treatment regimens of rFVIIa in GT patients with normal 
plasma coagulation pathways. We need data on rFVIIa as 
an independent treatment modality especially in patients 
refractory to platelet transfusion, or as an adjunct to other 
hemostatic treatment including platelet transfusion. The 
data also need to be stratiﬁ  ed according to mild/moderate 
and severe bleeding episodes, as well as minor and major 
surgical procedures. At this time the efﬁ  cacy of high dose 
rFVIIa can only be followed by clinical observations. There 
is therefore a need to ﬁ  nd laboratory parameters that will 
predict clinical efﬁ  cacy.
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